

Chemo- und Immuntherapie: Ist die Zystektomie bald überholt?

Leubet Yirga, Claudia Kesch, Viktor Grünwald

Literatur

1. Robert Koch Institut udGdeKiDeV. Krebs in Deutschland. 2015
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol.* 2001;19: 666–75
3. Mark D. Tyson II M, Daniel A. Barocas, MD, MPHb. Quality of Life After Radical Cystectomy. *Urologic Clinics of North America.* 2018; 45
4. Ben Hassine A, Souli I, Braiki R, Chouigui R, Amira A, Laaroussi H, et al. Quality of life in men after total cystoprostatectomy: Perceptions of Tunisian patients. *Can Oncol Nurs J.* 2019; 29: 226–231
5. Cerruto MA, D'Elia C, Siracusano S, Gedeshi X, Mariotto A, Iafrate M, et al. Systematic review and meta-analysis of non RCT's on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit. *Eur J Surg Oncol.* 2016; 42: 343–360
6. Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. *Cancer.* 2019; 125: 3155–3163
7. Culine S, Gravis G, Flechon A, Soulie M, Guy L, Laguerre B, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses. *Journal of Clinical Oncology.* 2020; 38(6_suppl): 437
8. Salminen AP, Montoya Perez I, Klén R, Ettala OO, Syvänen KT, Elo LL, et al. Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. *Bladder Cancer.* 2019; 5: 273–9
9. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *J Clin Oncol.* 2011; 29: 2432–8
10. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 2020, AWMF-

Registrierungsnummer 032/038OL, 2020 [Available from: <https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/> (abgerufen 29.04.2021)]

11. A. Witjes (Chair) HMB, R. Cathomas, E. Comp erat, N.C. Cowan, J.A. Efstathiou, R. Fietkau, G. Gakis, V. Hern andez, A. Lorch, M.I. Milowsky, M.J. Ribal (Vice-chair), G.N Thalmann, A.G. van der Heijden, E. Veskim ae, Guidelines Associates: E. Linares Espin os MR, Y. Neuzillet. EAU Guidelines Muscle-invasive and Metastatic Bladder Cancer. Arnhem, The Netherlands.: EAU Guidelines Office; 2021
12. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, R odel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol.* 2014; 66: 120–137
13. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. *Eur Urol.* 2012; 61: 705–11
14. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, R odel CM, et al. Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. *European Urology.* 2014; 66: 120–37
15. Dunst J, Sauer R, Schrott KM, K uhn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. *Int J Radiat Oncol Biol Phys.* 1994; 30: 261–6
16. Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ull en A, Nilsson S, et al. Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer. *European Urology.* 2012; 61: 1229–38
17. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. *New England Journal of Medicine.* 2020; 383: 1218–30
18. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *New England Journal of Medicine.* 2017; 376: 1015–26
19. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. *Ann Oncol.* 2019; 30: 970–6
20. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian  R, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol.* 2018; 36: 3353–3360

21. Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. *Nat Med.* 2019; 25: 1706–14
22. Cathomas R, Petrausch U, Hayoz S, Schneider M, Schardt JA, Seiler R, et al. Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17). *Journal of Clinical Oncology.* 2020; 38(6_suppl): 499
23. Grande E, Guerrero F, Puente J, Galante I, Duran I, Dominguez M, et al. DUTRENEO Trial: A randomized phase II trial of DURvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. *Journal of Clinical Oncology.* 2020; 38 (15_suppl): 5012
24. van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. *Nature Medicine.* 2020; 26: 1839–1844
25. Bandini M, Gibb EA, Gallina A, Raggi D, Marandino L, Bianchi M, et al. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study. *Annals of Oncology.* 2020; 31: 1755–63
26. Muro XGd, Valderrama BP, Medina A, Cuellar MA, Etxaniz O, Sarrió RG, et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial. *Journal of Clinical Oncology.* 2021; 39 (15_suppl): 4505
27. Balar AV, Milowsky MI, O'Donnell PH, Alva AS, Kollmeier M, Rose TL, et al. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial. *Journal of Clinical Oncology.* 2021; 39 (15_suppl): 4504
28. Galsky MD, Daneshmand S, Chan KG, Dorff TB, Cetnar JP, Neil BO, et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257. *Journal of Clinical Oncology.* 2021; 39 (15_suppl): 4503
29. Dash A, Pettus JAt, Herr HW, Bochner BH, Dalbagni G, Donat SM, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. *Cancer.* 2008; 113: 2471–2477
30. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer

(ABC) meta-analysis collaboration. *Eur Urol.* 2005; 48: 202–205; discussion 5-6

31. Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu J-J, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. *Urol Oncol.* 2015; 33 (5): 204.e1-.e2047
32. Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *Eur Urol.* 2020; 77: 439–46